NCT05844813Enrolling By Invitation4 期
Neoadjuvant Chemotherapy Combined With Targeted Treatment in High-risk Retroperitoneal Sarcoma-- A Nationwide Multicentered Prospective Controlled Study
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- Enrolling By Invitation
- 入组人数
- 102
- 试验地点
- 6
- 主要终点
- 3-year Progression Free Survival(PFS)
研究概览
简要总结
The goal of this clinical trial is to explore the potential survival benefits of neoadjuvant chemotherapy combined with target treatments followed by radical surgery in patients with primary high-risk/grade retroperitoneal sarcoma.
The main questions it aims to answer are:
- Whether the 1,3-year progression-free survival time(PFS) is prolonged in the neoadjuvant therapy group, compared with the surgery-only group.
- The Overall survival time in the two groups.
- The safety and tolerance in the neoadjuvant therapy group.
Participants will be allocated into two groups once they meet the inclusion criteria.
- Surgery-only Group: Patients will directly undergo surgeries after the confirmation of diagnosis through pre-operative biopsy.
- Neoadjuvant therapy group: Patients will receive the neoadjuvant chemotherapy combined with target treatment for three circles before the following sarcoma resectional surgeries.
研究设计
- 研究类型
- Interventional
- 分配方式
- Non Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 75 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Histologically proven primary high-risk Retroperitoneal sarcoma(RPS) (Including Dedifferentiated liposarcoma (DDLPS), leiomyosarcoma(LMS), Undifferentiated pleomorphic sarcoma(UPS), Solitary fibrous tumor(SFT)).
- •Primary localized RPS without histories of surgical resection, chemo- or radio-therapy, targeted therapy. Patients who underwent laparotomy with biopsy only will also be considered as primary cases.
- •Without histories of second malignant tumors.
- •Diagnosis should be confirmed based on MDM2(Mouse double minute 2 homolog) and CDK4(Cyclin-dependent kinase 4) expression on IHC (immunohistochemistry), while MDM2 amplification in the Fish test is highly recommended.
- •All grade 2-3 DDLPS can be included.
- •All grades of LMS can be included.
- •Tumor size ≥10cm
- •In UPS or SFT
- •All grades of UPS can be included.
- •High-risk SFT with a score ≥6 in 'Risk stratification of SFT for development of metastasis' introduced in The 5th edition of the WHO(World Health Organization) Soft tissue sarcoma classification.
- •Sarcoma without protruding across the diaphragm
- •Possibility of R0/R1 resection evaluated through preoperative MDT(multi-disciplinary team) discussion
- •No multi-organ or system dysfunction/failure or patients with slight dysfunction of organ/system could be easily recovered
- •Tolerable of chemotherapy and surgery through MDT evaluation and tests.
- •American Society of Anesthesiologist (ASA) ≤3
- •Fully understand the informs and consent to participate in the study.
排除标准
- •Sarcoma confirmed originating from the GI tract, uterus, or urinal tract.
- •Patients included in the study through preoperative biopsy or MDT discussion, with WDLPS, grade 1 LPS, or other types of tumors not mentioned in the Inclusion criteria evaluating through final pathological findings.
- •Sarcoma protruded into the chest cavity evaluated through preoperative imaging or surgical reports.
- •Metastasis confirmed pathologically or highly suspicious metastatic lesions through radiological findings, PET-CT(Positron emission tomography) is highly recommended, MDT discussion and evaluation are needed.
- •Histories of administration of Anthracyclines, Ifosfamide, and targeted agents.
- •Severe contradiction to surgery and chemotherapies, including persistent myelosuppression, myocardial/cerebral/pulmonary infarction, uncontrolled cardiac arrhythmia, etc within the last 6 months
- •Indication of severe infection or undergoing surgeries with high-risk hemorrhages in one month.
- •Persistent one or more organ or system dysfunctions, could not be recovered prior to the study.
- •Female patients who are pregnant or breastfeeding or female and male patients of reproductive potential who are not willing to employ effective birth control methods.
- •Patients with psychological conditions
研究组 & 干预措施
The Neoadjuvant Therapy Group
Experimental
Neoadjuvant chemotherapy + Target therapy+ Radical resectional Surgery Drugs: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide 1g/㎡ d1-5, Anlotinib10mg d1-14 Q3weeks * 3 Circles, Watch-Wait 4-6 weeks
干预措施: Doxorubicin+Ifosfamide+Anlotinib(AI+A) (Drug)
The Neoadjuvant Therapy Group
Experimental
Neoadjuvant chemotherapy + Target therapy+ Radical resectional Surgery Drugs: Doxorubicin（PLD） 40mg/㎡ d1, Ifosfamide 1g/㎡ d1-5, Anlotinib10mg d1-14 Q3weeks * 3 Circles, Watch-Wait 4-6 weeks
干预措施: Radical Surgery (Procedure)
The Surgery only Group
Active Comparator
Procedure: Radical resectional surgery
干预措施: Radical Surgery (Procedure)
结局指标
主要结局
3-year Progression Free Survival(PFS)
时间窗: 3 years after first patient enrolled in
Progression free survival will be measured from the date of surgery to the date of progression or death, whichever occurs first.
次要结局
- 1-year PFS(1year after first patient enrolled in.)
- 5-year OS(5 years after first patient enrolled in)
- Safety and toxicity of neoadjuvant therapy(1-d, 7-d after the first date of each neoadjuvant therapy session.)
- Postoperative morbidities(30-d, 90-d, 1-year separately after the date of surgery.)
- 5-year PFS(5 years after first patient enrolled in.)
- 1 year Overall survival(OS)(1year after first patient enrolled in)
- 3-year OS(3 years after first patient enrolled in)
研究者
Jun Chen
MD
Peking University International Hospital
研究点 (6)
Loading locations...
相似试验
招募中
2 期
Neoadjuvant Chemotherapy Plus Sequential Immune Checkpoint Inhibitor (ICI) Therapy in Locally Advanced Colon CancerColon CancerNCT06368141Ruijin Hospital56
招募中
3 期
Induction Chemotherapy Combined With Immunotherapy Followed by Concurrent Chemoradiation in Advanced Cervical CancerCervical CancerNCT05173272Sichuan Cancer Hospital and Research Institute286
招募中
2 期
A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally Advanced Rectal CancerLocally Advanced Rectal CarcinomaNCT06312982Beijing Friendship Hospital375
Unknown
2 期
FOLFOX6 as Neoadjuvant Chemotherapy in Local Advanced Gastric CancerEffects of ChemotherapySurgeryGastric CancerNCT02226380Peking Union Medical College Hospital75
Unknown
2 期
A Phase II Study of Neoadjuvant Chemotherapy Plus Durvalumab (MEDI4736) and Tremelimumab in Advanced-stage Ovarian Cancer (TRU-D)Ovarian Cancer Stage IIICOvarian Cancer Stage IVNCT03899610Yonsei University24